[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07614984":3,"trial-entities:NCT07614984":346,"trial-summary:NCT07614984":351},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":52,"secondary_outcomes":68,"sex":95,"minimum_age":96,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":97,"std_ages":112,"locations":115,"central_contacts":332,"overall_officials":337,"references":341,"see_also_links":342},"NCT07614984","7262-004","A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)","RECRUITING","2027-10-12","2026-07","2026-08-03","2026-06-30","Merck Sharp & Dohme LLC","INDUSTRY",false,"Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C).\n\nThe goals of this trial are to evaluate:\n\n* if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood\n* if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood\n* the safety and tolerability of taking MK-7262 and enlicitide alone and together",null,[19],"Lipoprotein(a)",[],"INTERVENTIONAL","TREATMENT",[24],"PHASE2",{"count":26,"type":27},750,"ESTIMATED",[29,38,45,49],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":36},"DRUG","MK-7262","Oral Coated Tablet",[34,35],"MK-7262 + enlicitide","MK-7262 monotherapy",[37],"HRS-5346",{"type":30,"name":39,"description":32,"armGroupLabels":40,"otherNames":42},"Enlicitide",[34,41],"enlicitide monotherapy",[43,44],"MK-0616","enlicitide decanoate",{"type":30,"name":46,"description":32,"armGroupLabels":47},"Placebo for MK-7262",[48,41],"Placebo",{"type":30,"name":50,"description":32,"armGroupLabels":51},"Placebo for enlicitide",[35,48],[53,57,60,64],{"measure":54,"description":55,"timeFrame":56},"Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).","Baseline and Week 8",{"measure":58,"description":59,"timeFrame":56},"Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.",{"measure":61,"description":62,"timeFrame":63},"Number of Participants who Experience One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.","Up to approximately 20 Weeks",{"measure":65,"description":66,"timeFrame":67},"Number of Participants Who Discontinue Study Intervention Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.","Up to approximately 12 Weeks",[69,72,75,78,81,85,88,92],{"measure":70,"description":71,"timeFrame":56},"Percent Change from Baseline in LDL-C at Week 8 (enlicitide monotherapy vs. placebo)","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with enlicitide monotherapy versus placebo.",{"measure":73,"description":74,"timeFrame":56},"Percent Change from Baseline in LDL-C at Week 8 (MK-7262 monotherapy vs. placebo)","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with MK-7262 monotherapy versus placebo.",{"measure":76,"description":77,"timeFrame":56},"Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. MK-7262 monotherapy)","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in Lp(a) between participants treated with MK-7262 + enlicitide versus MK-7262 monotherapy.",{"measure":79,"description":80,"timeFrame":56},"Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. enlicitide monotherapy)","Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with MK-7262 + enlicitide versus enlicitide monotherapy.",{"measure":82,"description":83,"timeFrame":84},"Percentage of Participants with Lp(a) \u003C125 nmol\u002FL at Week 8","Blood samples will be collected at Week 8 to assess the percentage of participants who have Lp(a) \\\u003C125 nmol\u002FL. The percentage of participants with Lp(a) \\\u003C125 nmol\u002FL at week 8 will be reported.","Week 8",{"measure":86,"description":87,"timeFrame":84},"Percentage of Participants with Lp(a) \u003C75 nmol\u002FL at Week 8","Blood samples will be collected at Week 8 to assess the percentage of participants who have Lp(a) \\\u003C75 nmol\u002FL. The percentage of participants with Lp(a) \\\u003C75 nmol\u002FL at week 8 will be reported.",{"measure":89,"description":90,"timeFrame":91},"Percent Change from Baseline in Lp(a) at Week 12","Blood samples will be collected at baseline and at Week 12 to assess the mean percent change from baseline in Lp(a).","Baseline and Week 12",{"measure":93,"description":94,"timeFrame":91},"Percent Change from Baseline in LDL-C at Week 12","Blood samples will be collected at baseline and at Week 12 to assess the mean percent change from baseline in LDL-C.","ALL","18 Years",{"inclusion":98,"exclusion":101,"raw_text":111},[99,100],"Has Lp(a) ≥ 150 nmol\u002FL","Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study",[102,103,104,105,106,107,108,109,110],"Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH","Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization","Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)","Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection","Has a history of nephrotic syndrome","Has severe renal insufficiency","Has received certain therapies in the prohibited timeframe as specified in the protocol","Has active or chronic hepatobiliary or hepatic disease","Has poorly controlled Type 1 or Type 2 diabetes","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has Lp(a) ≥ 150 nmol\u002FL\n* Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH\n* Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization\n* Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)\n* Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection\n* Has a history of nephrotic syndrome\n* Has severe renal insufficiency\n* Has received certain therapies in the prohibited timeframe as specified in the protocol\n* Has active or chronic hepatobiliary or hepatic disease\n* Has poorly controlled Type 1 or Type 2 diabetes",[113,114],"ADULT","OLDER_ADULT",[116,130,140,151,161,172,183,193,203,213,223,234,244,255,266,277,288,299,310,321],{"facility":117,"status":8,"city":118,"state":119,"zip":120,"country":121,"contacts":122,"geoPoint":127},"Advanced Cardiovascular - Alexander City ( Site 0158)","Alexander City","Alabama","35010","United States",[123],{"name":124,"role":125,"phone":126},"Study Coordinator","CONTACT","256-215-5323",{"lat":128,"lon":129},32.94401,-85.95385,{"facility":131,"status":8,"city":132,"state":119,"zip":133,"country":121,"contacts":134,"geoPoint":137},"AMR Clinical Mobile ( Site 0149)","Mobile","36608",[135],{"name":124,"role":125,"phone":136},"251-414-1984",{"lat":138,"lon":139},30.69436,-88.04305,{"facility":141,"status":8,"city":142,"state":143,"zip":144,"country":121,"contacts":145,"geoPoint":148},"National Heart Institute ( Site 0113)","Beverly Hills","California","90211-2285",[146],{"name":124,"role":125,"phone":147},"310-289-5221",{"lat":149,"lon":150},34.07362,-118.40036,{"facility":152,"status":8,"city":153,"state":143,"zip":154,"country":121,"contacts":155,"geoPoint":158},"Headlands Research CTR Lincoln ( Site 0127)","Lincoln","95648",[156],{"name":124,"role":125,"phone":157},"916-434-8230",{"lat":159,"lon":160},38.89156,-121.29301,{"facility":162,"status":8,"city":163,"state":164,"zip":165,"country":121,"contacts":166,"geoPoint":169},"Chase Medical Research, LLC ( Site 0163)","Waterbury","Connecticut","06708",[167],{"name":124,"role":125,"phone":168},"203-419-4420",{"lat":170,"lon":171},41.55815,-73.0515,{"facility":173,"status":8,"city":174,"state":175,"zip":176,"country":121,"contacts":177,"geoPoint":180},"Soffer Health Institute ( Site 0123)","Hollywood","Florida","33020",[178],{"name":124,"role":125,"phone":179},"305-250-2106",{"lat":181,"lon":182},26.0112,-80.14949,{"facility":184,"status":8,"city":185,"state":175,"zip":186,"country":121,"contacts":187,"geoPoint":190},"Westside Center for Clinical Research ( Site 0161)","Jacksonville","32205",[188],{"name":124,"role":125,"phone":189},"904-693-1490",{"lat":191,"lon":192},30.33218,-81.65565,{"facility":194,"status":8,"city":195,"state":175,"zip":196,"country":121,"contacts":197,"geoPoint":200},"Inpatient Research Clinic ( Site 0110)","Miami Lakes","33014",[198],{"name":124,"role":125,"phone":199},"786-502-4303",{"lat":201,"lon":202},25.90871,-80.30866,{"facility":204,"status":8,"city":205,"state":175,"zip":206,"country":121,"contacts":207,"geoPoint":210},"Clinical Research Trials of Florida ( Site 0101)","Tampa","33607",[208],{"name":124,"role":125,"phone":209},"813-873-8102",{"lat":211,"lon":212},27.94752,-82.45843,{"facility":214,"status":8,"city":215,"state":175,"zip":216,"country":121,"contacts":217,"geoPoint":220},"Conquest Research LLC ( Site 0140)","Winter Park","32789",[218],{"name":124,"role":125,"phone":219},"407-916-0060",{"lat":221,"lon":222},28.6,-81.33924,{"facility":224,"status":8,"city":225,"state":226,"zip":227,"country":121,"contacts":228,"geoPoint":231},"Flourish Research - Bowie ( Site 0106)","Bowie","Maryland","20715",[229],{"name":124,"role":125,"phone":230},"410-824-1341",{"lat":232,"lon":233},38.94278,-76.73028,{"facility":235,"status":8,"city":236,"state":226,"zip":237,"country":121,"contacts":238,"geoPoint":241},"Velocity Clinical Research Rockville ( Site 0146)","Rockville","20854",[239],{"name":124,"role":125,"phone":240},"240-698-2800",{"lat":242,"lon":243},39.084,-77.15276,{"facility":245,"status":8,"city":246,"state":247,"zip":248,"country":121,"contacts":249,"geoPoint":252},"Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132)","Troy","Michigan","48098",[250],{"name":124,"role":125,"phone":251},"248-312-0025",{"lat":253,"lon":254},42.60559,-83.14993,{"facility":256,"status":8,"city":257,"state":258,"zip":259,"country":121,"contacts":260,"geoPoint":263},"Montana Medical Research, Inc. ( Site 0156)","Missoula","Montana","59808",[261],{"name":124,"role":125,"phone":262},"406-549-1124",{"lat":264,"lon":265},46.87215,-113.994,{"facility":267,"status":8,"city":268,"state":269,"zip":270,"country":121,"contacts":271,"geoPoint":274},"New Mexico Clinical Research & Osteoporosis Center ( Site 0119)","Albuquerque","New Mexico","87106",[272],{"name":124,"role":125,"phone":273},"505-855-5505",{"lat":275,"lon":276},35.08449,-106.65114,{"facility":278,"status":8,"city":279,"state":280,"zip":281,"country":121,"contacts":282,"geoPoint":285},"Velocity Clinical Research, Durham ( Site 0145)","Durham","North Carolina","27701",[283],{"name":124,"role":125,"phone":284},"919-503-4711",{"lat":286,"lon":287},35.99403,-78.89862,{"facility":289,"status":8,"city":290,"state":291,"zip":292,"country":121,"contacts":293,"geoPoint":296},"Remington-Davis, Inc. ( Site 0107)","Columbus","Ohio","43215",[294],{"name":124,"role":125,"phone":295},"614-487-2560",{"lat":297,"lon":298},39.96118,-82.99879,{"facility":300,"status":8,"city":301,"state":302,"zip":303,"country":121,"contacts":304,"geoPoint":307},"Holston Medical Group ( Site 0117)","Kingsport","Tennessee","37660",[305],{"name":124,"role":125,"phone":306},"423-857-2789",{"lat":308,"lon":309},36.54843,-82.56182,{"facility":311,"status":8,"city":312,"state":313,"zip":314,"country":121,"contacts":315,"geoPoint":318},"Carient Heart & Vascular - Manassas ( Site 0165)","Manassas","Virginia","20109",[316],{"name":124,"role":125,"phone":317},"571-581-1771",{"lat":319,"lon":320},38.75095,-77.47527,{"facility":322,"status":8,"city":323,"state":324,"zip":325,"country":121,"contacts":326,"geoPoint":329},"Rainier Clinical Research Center ( Site 0116)","Renton","Washington","98057",[327],{"name":124,"role":125,"phone":328},"425-251-1720",{"lat":330,"lon":331},47.48288,-122.21707,[333],{"name":334,"role":125,"phone":335,"email":336},"Toll Free Number","1-888-577-8839","Trialsites@merck.com",[338],{"name":339,"affiliation":13,"role":340},"Medical Director","STUDY_DIRECTOR",[],[343],{"label":344,"url":345},"Merck Clinical Trials Information","http:\u002F\u002Fwww.merckclinicaltrials.com",{"nct_id":4,"conditions":347,"biomarkers":349},[348],"A",[350],"Lipoprotein (a)",{"nct_id":4,"found":352,"summary":353,"prompt_version":363},true,{"design":354,"status":355,"heading":356,"summary":357,"follow_up":358,"word_count":359,"commitments":360,"compensation":361,"drugs_mentioned":362},"This is an interventional study planning to enroll 750 participants. It will compare MK-7262 and enlicitide, alone and together, against placebo.","completed","Clinical Trial of MK-7262 and Enlicitide for High Lipoprotein(a)","This study is testing two trial medicines, MK-7262 and enlicitide, to see if they can lower high levels of Lipoprotein(a) (Lp(a)) and LDL-C (bad cholesterol). Researchers want to know if these medicines work better than a placebo (an inactive pill) when taken alone or together, and if they are safe. You may be able to join if you are 18 or older, have Lp(a) levels of 150 nmol\u002FL or higher, and are on a stable dose of statin medication. The study will measure changes in Lp(a) and LDL-C at 8 weeks, and track any side effects for about 20 weeks. The current status of this study is unclear.","Your Lp(a) and LDL-C levels will be measured at 8 weeks. Safety will be monitored for up to approximately 20 weeks.",108,"Not specified in the trial record.","Not stated in the trial record.",[31,39],"v2"]